RMD ResMed (RMD) Q4 FY26 earnings call
ResMed delivered strong Q4 FY26 results with robust revenue and EPS growth, driven by device and mask sales. The company is actively managing its portfolio through the acquisition of Noctrix and the divestiture of MatrixCare, while significantly increasing capital returns to shareholders. FY27 guidance reflects continued core business growth, partially offset by the strategic suspension of Astral sales.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
RMD operating KPIs by quarter
| KPI | Dec 2024 Q2 FY25 | Mar 2025 Q3 FY25 | Mar 2026 Q3 FY26 | This call Jun 2026 Q4 FY26 | Change vs prior quarter |
|---|---|---|---|---|---|
| Employees | 10KThank you to all the 10,000 ResMedians for your hard work and dedication to make our mission possible.Source: earnings call transcript | 10K+Thanks to the over 10,000 ResMedians who make that happen by delivering products and services to serve patients in over 140 countries worldwide.Source: earnings call transcript | 10K+On behalf of our ResMed Board and over 10,000 ResMedians in 140 countries, I'd like to thank Brett, who I've had the privilege to partner with for 26 years, including the last 55 quarters as a CEO and CFO team.Source: earnings call transcript | 11K+I am so impressed by the talent of the more than 11,000 ResMedians around the world and their commitment to serving patients.Source: earnings call transcript | — |
Operating figures the company stated on at least two of the calls shown, checked against each call's transcript. Click a figure to read the sentence. A dash means it was not stated that quarter.
Inve summary of the company's earnings call; see how call summaries are prepared. Not investment advice.